Valuation: Agenus Inc.

Market Cap 209M 182M 168M 155M 292M 20.09B 299M 2.01B 791M 9.84B 784M 766M 33.87B P/E 2026 *
7.53x
P/E 2027 * -31.3x
Enterprise Value 209M 182M 168M 155M 292M 20.09B 299M 2.01B 791M 9.84B 784M 766M 33.87B EV / Sales 2026 *
1.13x
EV / Sales 2027 * 1.59x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+0.20%
1 week+49.55%
Current month+63.73%
1 month+69.26%
3 months+4.59%
6 months+50.00%
Current year+59.55%
1 week 4.66
Extreme 4.655
8.7
1 month 2.85
Extreme 2.85
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
34.8
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Chief Executive Officer

4,852 0.0117%
01/07/26 Free

Director

8,547 0.0205%
01/07/26 Free

Director

2,268 0.0054%
Change 5-day change 1-year change 3-year change Capi.($)
+0.20%+49.55%-25.45%-85.52% 209M
+3.90%-0.39%+376.72%+599.59% 39.58B
-1.70%+4.46%+7.46%+57.67% 34.69B
-2.01%-0.76%+26.35%-6.83% 34.42B
+0.06%+0.34%+2.32%+29.30% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 14.05B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average +0.19%+4.99%+195.47%+150.03% 20.64B
Weighted average by Cap. +0.24%+0.41%+171.21%+187.12%

Financials

2026 *2027 *
Net sales 185M 161M 149M 137M 259M 17.79B 265M 1.78B 700M 8.71B 694M 678M 29.99B 131M 115M 106M 97.71M 184M 12.66B 188M 1.27B 498M 6.2B 494M 483M 21.34B
Net income 44.8M 39.15M 36.13M 33.3M 62.76M 4.31B 64.16M 432M 170M 2.11B 168M 165M 7.27B -17.8M -15.56M -14.35M -13.23M -24.94M -1.71B -25.49M -172M -67.48M -840M -66.85M -65.38M -2.89B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
17/07/26 US$5.010 +0.20% 1,754,750
16/07/26 US$5.000 -0.20% 2,696,460
15/07/26 US$5.010 -1.38% 4,491,064
14/07/26 US$5.080 -16.99% 11,110,968
13/07/26 US$6.120 +82.69% 174,277,926
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.010USD
Average target price
30.00USD
Spread / Average Target
+498.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock